A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations.
Epidemiology
Inflammatory bowel disease
Nationwide Inpatient Sample
Obesity
Outcomes
Journal
Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
17
03
2021
accepted:
05
05
2021
pubmed:
21
5
2021
medline:
21
5
2021
entrez:
20
5
2021
Statut:
ppublish
Résumé
Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes. For 2016-2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system. We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40-65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort. Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
METHODS
METHODS
For 2016-2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
RESULTS
RESULTS
We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40-65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
CONCLUSIONS
CONCLUSIONS
Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.
Identifiants
pubmed: 34011019
pii: ir.2021.00046
doi: 10.5217/ir.2021.00046
pmc: PMC9344244
doi:
Types de publication
Journal Article
Langues
eng
Pagination
342-349Références
JAMA. 2010 Jan 20;303(3):235-41
pubmed: 20071471
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
Inflamm Bowel Dis. 2015 Dec;21(12):2857-63
pubmed: 26241001
Appl Health Econ Health Policy. 2019 Feb;17(1):77-91
pubmed: 30259396
Clin Gastroenterol Hepatol. 2018 Feb;16(2):190-197.e11
pubmed: 28603049
Age (Dordr). 2016 Feb;38(1):23
pubmed: 26846415
Diabetes Metab Syndr Obes. 2010 Aug 30;3:285-95
pubmed: 21437097
Gastroenterol Hepatol (N Y). 2020 Jul;16(7):350-359
pubmed: 34035739
Gastroenterology. 2018 Oct;155(4):1079-1089.e3
pubmed: 29958857
Intest Res. 2018 Jan;16(1):26-42
pubmed: 29422795
MMWR Morb Mortal Wkly Rep. 2019 Dec 13;68(49):1134-1138
pubmed: 31830006
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Ann Transl Med. 2017 Apr;5(7):161
pubmed: 28480197
Res Health Sci. 2018;3(3):65-78
pubmed: 30079383
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121
pubmed: 27899815
N Engl J Med. 2011 Mar 17;364(11):987-9
pubmed: 21410367
Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751
pubmed: 29562277
J Inflamm Res. 2014 Jun 23;7:113-20
pubmed: 25075198
Clin J Gastroenterol. 2020 Apr;13(2):139-152
pubmed: 31452062
Diabetes. 2011 Nov;60(11):2667-8
pubmed: 22025771
World J Gastroenterol. 2019 Jun 14;25(22):2788-2798
pubmed: 31236001
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
Proc (Bayl Univ Med Cent). 2019 Feb 1;32(1):14-17
pubmed: 30956572
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006